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Peroxisomal and mitochondrial malfunction, which are highly intertwined through redox regulation, in
combination with defective proteostasis, are hallmarks of the most prevalent multifactorial neurode-
generative diseases—including Alzheimer’s (AD) and Parkinson’s disease (PD)—and of the aging process,
and are also found in inherited conditions. Here we review the interplay between oxidative stress and
axonal degeneration, taking as groundwork recent ﬁndings on pathomechanisms of the peroxisomal
neurometabolic disease adrenoleukodystrophy (X-ALD). We explore the impact of chronic redox im-
balance caused by the excess of very long-chain fatty acids (VLCFA) on mitochondrial respiration and
biogenesis, and discuss how this impairs protein quality control mechanisms essential for neural cell
survival, such as the proteasome and autophagy systems. As consequence, prime molecular targets in the
pathogenetic cascade emerge, such as the SIRT1/PGC-1α axis of mitochondrial biogenesis, and the in-
hibitor of autophagy mTOR. Thus, we propose that mitochondria-targeted antioxidants; mitochondrial
biogenesis boosters such as the antidiabetic pioglitazone and the SIRT1 ligand resveratrol; and the au-
tophagy activator temsirolimus, a derivative of the mTOR inhibitor rapamycin, hold promise as disease-
modifying therapies for X-ALD.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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First described by Rhodin in 1954 and then isolated by de Duve in
1966, the peroxisome is an organelle derived from the endoplasmic
reticulum [1,2]. In contrast to mitochondria, they have single rather
than double membranes, and lack DNA. They are essential organelles
of eukaryotic origin, ubiquitously distributed in cells and organisms,
playing key roles in multiple metabolic pathways including de-
gradation of long-chain and very long-chain fatty acids (LCFA, VLCFA
(CZ22:0)) by α- or β-oxidation; hydrogen peroxide detoxiﬁcation;
degradation of amino acids, methanol and purines; or in the synthesis
of bile acids and essential polyunsaturated fatty acids. Loss or mal-
function of peroxisomes causes more than 20 fatal inherited condi-
tions including Zellweger’s syndrome and X-linked adrenoleukody-
strophy (X-ALD) (See also www.peroxisomedb.org) [3,4]. Classical
hallmarks of peroxisomal dysfunction with pathogenic implications
are an excess of VLCFA, which generates oxidative stress and mi-
tochondrial toxicity and will be addressed in detail in this review; a
decrease of the ω3-polyunsuaturated fatty acid: C22:6ω3 (DHA), and a
decrease in ether lipids called plasmalogens, both synthetized in
peroxisomes, and bearing neuroprotective, neurotrophic and anti-
oxidant functions [5–7]. Human peroxisomes contain 85 proteins,
such as the peroxins (PEX) which are involved in peroxisome bio-
genesis and dynamics; three ATP-binding cassette transporters sub-
familiy D or ABCD transporters (ABCD1, ABCD2 and ABCD3), which
import fatty acids into the peroxisome which will undergo a process
of synthesis or degradation through beta-oxidation; and several ma-
trix enzymes which catalize these processes. A complex PEX inter-
action network controls peroxisome biogenesis (Pex23, Pex24, Pex25,
Pex27, Pex28, Pex29, Pex30, Pex31 and Pex32); ﬁssion (Pex11,Pex25,
Pex27 and Pex34); formation of peroxisomal membrane from the ER
(Pex1, Pex3, Pex6, Pex16, Pex19, Pex23, Pex25 and Pex30); targeting of
matrix proteins (Pex5, Pex7, Pex18, Pex20 and Pex21), matrix protein
import (Pex1, Pex2, Pex4, Pex5, Pex6, Pex8, Pex10, Pex12, Pex13,
Pex14, Pex15, Pex17, Pex22, Pex26 and Pex33) and direct targeting of
peroxisomal membrane proteins (Pex3 and Pex19) [3,8,9]. The ABCD
transporters serve as active uptake of mainly very long-chain fatty
acids (VLCFA) and VLCFA-CoA for ABCD1 [10–12]; of long-chain sa-
turated and omega9-monounsaturated fatty acids, and precursors of
docosahexanoic acid (DHA) for ABCD2 [13,14]; and ofbranched-chain
fatty acids and C27 bile acids for ABCD3 [15]. These transporters must
form homo or heterodimers to function [16]. The high degree of
homology of the three ABCD transporters accounts for overlapping
fatty acid speciﬁcities when overexpressed [17,18]; Lately, interactions
of ABCD1 with proteins involved in fatty acid synthesis (FASN, ACLY,
ACC) and activation (FATP4) have been described, which suggests that
a novel fatty acid synthesis-transport complex functions at the cyto-
plasmic side of the peroxisomal membrane [19].2. X-linked adrenoleukodystrophy and redox homeostasis
2.1. The disease
X-ALD is the most common peroxisomal disorder and monogenic
leukodystrophy (OMIM 300100). Patients suffer from central in-
ﬂammatory demyelination in the brain and/or slowly progressing
axonal degeneration of the corticospinal tracts, resulting in spasticparaparesis [20–22]. X-ALD is caused by mutations in the ABCD1
gene (Xq28), which encodes the ATP-binding cassette transporter,
an integral peroxisomal membrane protein. The ABCD1 protein
imports very long-chain fatty acids and VLCFA-CoA esters into the
peroxisome for degradation [11,12]. The defective function of the
ABCD1 transporter leads to VLCFA excess due to decreased β-oxi-
dation of these fatty acids in peroxisomes [12,13], leading to a dis-
turbed fatty acid proﬁle in tissues and plasma, particularly involving
hexacosanoic acid (C26:0) and C26:0-containing lipids such as ly-
sophosphatidilcholine. These are used as pathognomonic markers
for the biochemical diagnosis of X-ALD [23,24].
Despite being a single-gene disease, X-ALD is a complex inherited
syndrome in which the same mutation in the ABCD1 gene can lead to
clinically very distinct phenotypes [20–22,25]. Loss-of-function mu-
tations in this protein are the cause of the disease, which is char-
acterised by three main distinct phenotypes. Cerebral childhood ALD
(cALD), which affects boys between 5 and 12 years of age, manifests
in 35% of all X-ALD patients and exhibits strong inﬂammatory de-
myelination with autoimmune components, leading to death within
few years. AMN is the most frequent manifestation of X-ALD and
affects adult patients. AMN patients present peripheral neuropathy
and distal axonopathy involving corticospinal tracts of the spinal cord
—but not brain neuroinﬂammation or major demyelination—with
spastic paraparesis as major symptoms. Intermediate forms with non-
inﬂammatory childhood cerebral demyelination occur, as do mixed
forms, with around 20% of all AMN patients developing a cerebral
inﬂammatory disease at later stages than in cALD. A majority of pa-
tients additionally suffer from adrenal insufﬁciency [20–22,25]. In-
terestingly, all clinical phenotypes can occur within the same family,
indicating that there is no direct phenotype–genotype correlation
[20–22,25]. Female carriers frequently develop AMN, with symptoms
such as myelopathy and peripheral neuropathy [26].
To date, the only treatment is allogeneic bone marrow trans-
plantation, which is associated with a high morbidity and mortality
and is available only to nearly-asymptomatic X-ALD children [27]. A
gene therapy approach using corrected hematopoietic stem cells
CD34þ , has proved to be successful and a good alternative to
transplant as it is less invasive [28]. This alternative treatment has the
same indications as bonemarrow transplantation, meaning that it can
be applied only to a small subset of patients with few to no symptoms
[29]. A novel gene therapy strategy uses adeno-associated virus ser-
otype 9 to express human ABCD1,which has yielded promising results
in a mouse model of X-ALD [30]. However, a recent report suggests
that allogeneic bone marrow transplant in cALD does arrest in-
ﬂammatory progression and death, but does not prevent the adult
AMN phenotype from developing AMN in adulthood [31].
Thus, for AMN patients there is no satisfactory treatment to
date. Oral administration of “Lorenzo’s oil” has been used, but its
clinical efﬁcacy and clinical indications have been controversial for
more than 15 years [32]. Nonetheless, more recent successful
pharmacological preclinical tests in the X-ALD mouse model
warrant translation into the clinic [33–36].
2.2. Mouse models for X-linked adrenoleukodystrophy: Lessons
learnt
The classical knockout of the murine Abcd1 gene, the X-ALD
mouse model, does not exhibit signs of demyelination in spite of
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shows instead a phenotype resembling the late-onset axonal de-
generation in spinal cords presented by most AMN patients,
characterised by spastic paraparesis due to degeneration of corti-
cospinal tracts, but without signs of active inﬂammatory demye-
lination in the brain. In the mouse, mainly axonal pathology is
detectable in sciatic nerves and long tracts of spinal cords, but not
in the brain [38]. This is correlated with slower motor nerve
conduction, and with disability signs in rotarod, treadmill, bar-
cross and clasping tests, of very late onset around 20 months of
age [18,34–36,39]. Thus, the phenotype of Abcd1- mice mimics
features of human AMN, providing a model for investigating dis-
ease pathogenesis. Also, this model provides evidences of axonal
degeneration prior to myelin degeneration, an important ﬁnding
that strongly suggests that the underlying phenotype in the hu-
man disease is AMN, with full penetrance at 50 years of age [40].
We generated double-mutants of Abcd1 and its closest homo-
log, the Abcd2 gene, which exhibits overlapping biochemical and
physiological functions with Abcd1 [13,41–44], and is able to
compensate for Abcd1 loss in vivo [40]. Abcd2 is thus a prime
therapeutic target [45–48]. These double mutant mice exhibited a
more pronounced and earlier-onset axonal degenerative pheno-
type, manifesting at around 12 months of age, what makes them
more suitable for therapeutic assays [18]. Both Abcd1- and Abcd1-/
Abcd2-/- mice are bona ﬁde models of mild, late-onset axonopathy
exhibited by AMN patients. These models are instrumental in
dissecting pathomechanisms of AMN [49–53] and importantly, in
pinpointing and evaluating tailored therapies [30,33–36,54].
It is worth mentioning that a non-negligeable degree of chronic
neuroinﬂammation with astrocytosis and microgliosis is present in
spinal cords of both, the Abcd1-null and more markedly, in the
double Abcd1/Abcd2 mouse model. Moreover, a functional geno-
mics approach carried out on the Abcd1 null model, has unraveled
a signature characterized by oxidative stress, mitochondrial dys-
regulation, adipocytokine signaling, and chronic inﬂammation
routes, including NFκB activation with production of proin-
ﬂammatory cytokines detected in spinal cords and plasma [53].
These ﬁndings challenge the notion that inﬂammatory reactions
only occur in the most severe forms of X-ALD, and provide a basis
to argue that a low-grade proinﬂammatory reaction initiated by
VLCFA and present in the mouse models and in AMN patients, may
adopt a more aggressive proﬁle should a second (or third or sev-
eral) hit appear [55]. These additional modiﬁer genes or epige-
netic, environmental or stochastic events that may ignite a full-
blown cerebral inﬂammatory demyelination rassembling cALD or
cAMN, have not been identiﬁed as of today. Thus, a suitable animal
model that serves as a tool for the development of therapeutic
strategies for the lethal stages of this disorder is still missing.
2.3. Oxidative damage and mitochondrial impairment in X-ALD
2.3.1. Early redox imbalance in X-ALD
Oxidative stress is deﬁned as a pathological condition that results
from a redox disequilibrium leading to an excess of ROS, which is
not adequately neutralized by the cellular antioxidant defenses. A
direct consequence of excessive ROS production is interaction with
cellular biomolecules — in particular DNA, lipids, and proteins —
which are then modiﬁed. Proteins can be directly damaged by ROS,
or indirectly by reaction with active aldehyde products of lipid
peroxidation — e.g. malondialdehyde (MDA) or hydroxynonenal —
or as a result of alterations in membrane lipid microenvironment
secondary to peroxidative processes. These changes are detrimental
if the modiﬁed residues are essential for the protein’s activity or
turnover [56]. Moreover, oxidative lesions can also transform lipid
properties and induce mutations in mitochondrial and nuclear DNA,
causing mitochondrial dysfunction and pathology [57].Taking advantage of the Abcd1- mouse model, and keeping
track of the data obtained with expression microarrays [53], we
uncovered an early-onset oxidative damage, which may be a major
contributor to disease pathogenesis in the mouse [33,49,55,58,59].
This is a common feature to neurodegenerative diseases and aging,
and is found in X-ALD patients in brain tissue as well as in per-
ipheral cells or ﬂuids such as ﬁbroblasts, erythrocytes, peripheral
mononuclear cells and plasma [46,58–62].
Abcd1- mice present accumulation of MDAL (malonaldehyde-
lysine), a consequence of lipoxidative damage to proteins, in spinal
cords as early as 3.5 months of age. At 12 months, Abcd1- mice
accumulate additional oxidative damage products arising from
metal-catalyzed oxidation and glycoxidation/lipoxidation to pro-
teins. We also detected several oxidatively modiﬁed proteins,
mostly belonging to Krebs cycle, oxidative phosphorylation (OX-
PHOS) and to glycolysis [52,63]. This was associated with de-
creased activities of pyruvate kinase, and lowered levels of ATP
and NADH, as well as reduced glutathione (GSH) [63]. Finally, a
wide array of mitochondrial genes related to the pyruvate and
oxoglutarate dehydrogenase complexes, tricarboxylic acid (TCA)
cycle, OXPHOS system and antioxidant defenses were found dys-
regulated in the functional genomics analysis [53].
Thus, in X-ALD we ﬁnd a prime example of intertwined redox
and metabolic homeostasis in the nervous system. Diminished
levels of ATP have also been described in AD and PD mouse models
[64,65], although the ratios of NAD/NADH, of paramount im-
portance, have not been systematically measured in most pre-
valent neurodegenerative diseases.
Importantly, we observed that the agent generating redox im-
balance was the raised levels of VLCFA. Indeed, when in excess,
C26:0 is able to generate ROS and decrease mitochondrial mem-
brane potential in human X-ALD ﬁbroblasts [49]. Similar studies
showed that VLCFA was able to depolarize mitochondria and in-
crease ROS in immortalized or primary neural cell cultures [66–69].
We thus tested a combination of carefully selected anti-oxidants
— N-acetylcysteine (NAC), α-lipoic acid (LA) and vitamin E — which
showed synergistic effects in vitro. Lipoic acid is of particular interest
as it is at the same time a ROS scavenger [70], and a cofactor of the
Krebs cycle enzyme α-keto-glutarate-dehydrogenase (αKGDH) [71],
which is oxidized in X-ALD [63]. Lately, lipoic acid has been shown
to rescue the hypometabolic state in a mouse model of AD, char-
acterized by low levels of glutamine, glutamate, aspartate and
N-acetylaspartate, metabolites of the TCA cycle [72]. We thus treated
the X-ALD mice with the cocktail above mentioned, and obtained a
neutralization of oxidative stress and lesions to proteins; preserved
bioenergetic homeostasis maintaining ATP and NADH levels by re-
covering normal levels of oxidation on key proteins of Krebs cycle
and glycolysis; halted signs of axonal degeneration in im-
munohistological stainings; and prevented locomotor impairment in
bar-cross and treadmill tests [33–36].
These results provide conceptual proof of C26:0 –induced oxida-
tive stress as a major causative disease-driving factor in X-ALD, thus
warranting translation into clinical trials for X-AMN patients and in-
viting assessment of antioxidant strategies in other diseases with
axonal degeneration in which oxidative damage may play a role. A
word of caution is however in order as several trials with antioxidants
have failed in AD, PD or ALS diseases [73,74]. Among the causes for
this may be that the magnitude of neuronal loss and synaptic dys-
function present by the time the full clinical syndrome is evident,
could overwhelm the functional beneﬁts brought by the treatment.
However, the treatment with idebenone, a synthetic analog of CoQ10,
has shown promise in patients with Leber hereditary optic neuro-
pathy (LHON) [75–78], mitochondrial encephalopathy, lactic acidosis
and stroke-like episodes (MELAS) [76,79], OPA1-mutant dominant
optic atrophy [80] or Friedreich ataxia (FRDA) [81–85], constituting a
good proof-of-principle accumulative evidence. Based on the results
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743 has been synthesized, which is 1000 to 10000 fold more potent
than CoQ10 [73]. EPI-743 is a para-benzoquinone which acts aug-
menting the synthesis of glutathione and optimizing metabolic con-
trol by regulating electron transport at the mitochondria. It has been
shown to be efﬁcacious at ameliorating symptoms in several inherited
mitochondria disease entities [86–88], and will be tested in a phase II
clinical trial on AMN patients starting in 2015.
2.3.2. NOXIOUS eFFECTS ON MIToCHONDRIA exerTED BY eXCESS OF
c26:0
A deﬁcient redox homeostasis linked to mitochondrial dys-
function is at the core of axonal degeneration in several neuro-
degenerative diseases [89,90], with a strong correlation between
the accumulation of damaged mitochondria with disease pro-
gression [91,92]. Mitochondria are both very sensitive to oxidative
damage and the main producers of ROS, in particular when the
mitochondrial electron transport chain (ETC) is malfunctioning.
Although the major ROS producer in mitochondria are ETC
(Complex I, and III) [92,93], other sites of mitochondrial ROS
production have been identiﬁed. Among these are p66Shc and
several enzymes such as NADPH oxidase, monoamine oxidase,
uncoupled neuronal NO synthase, aconitase, electron transfer ﬂa-
voprotein (ETF) and ETF quinone oxidoreductase (ETF dehy-
drogenase), dihydro-orotate dehydrogenase, α-glycerophosphate
dehydrogenase, α-ketoglutarate dehydrogenase complex (KGDHC)
and pyruvate dehydrogenase complex (PDHC) [92,93]. Notably,
several subunits of complex III and IV [52], and of KGDHC and
PDHC are oxidized [63] in the Abcd1 null mouse, which pre-
sumably leads to malfunction and most likely, to elevated pro-
duction of free radicals from these sites. In axons, mitochondria
provide a substantial part of the energy required during neuro-
transmission, and their transport towards ATP-demanding areas is
tightly regulated. Nonetheless, axonal mitochondria are more
vulnerable than their cellular counterparts, as mitochondria re-
quire from an elongated shape to ﬁt with the axon morphology,
and thus, are more reliant on fusion-ﬁssion events to exchange
material among them. An imbalance in the triad ROS/ATP/calcium
that overcomes the homeostatic capacity of the mitochondria in-
itiates a toxic cycle of events that will ultimately activate the ax-
onal degeneration program. For instance, mitochondrial ROS may
oxidize and inhibit the OXPHOS system, inducing a decline in the
ATP production. This energetic failure, in its turn, impairs the ATP-
dependent ionic pumps, triggering a massive calcium inﬂux. Fur-
thermore, ROS do not only impair the OXPHOS system but also
promote the opening of the mtPTP leading to a subsequent efﬂux
of calcium from the mitochondria to the cytosol. Calcium overload
in the cytoplasm triggers then calcium-dependent activation of
calpains. These proteases disassemble the microtubule structure
and impair the correct transport along the axon. All these events
will result in axonal swelling, loss of axonal continuity and even-
tually, axonal destruction [94].
In X-ALD, a very similar scenario takes place with unbalanced
ROS/ATP/Ca2þ homeostasis [95]. Mitochondria appear to be the
main source of ROS in X-ALD ﬁbroblasts when cells are exposed to
an excess of C26:0, as determined through measuring in-
tramitochondrial ROS by MitoSOX or by using mitochondrial un-
couplers. Excess of C26:0 also inhibits OXPHOS in ﬁbroblasts [52].
Defective OXPHOS was also observed in both 158 N oligoden-
drocytal cells and SK-NB-E neuronal cells when exposed to a
VLCFA excess [66,69], and in isolated brain mitochondria, which
increase ROS production, and diminished Ca2þ uptake capacity
[95]. However, we cannot rule out the intriguing possibility that
the observed ROS production by mitochondria is provoked by
signals originating in peroxisomes. Indeed, the redox status of
mitochondria is modiﬁed in catalase-deﬁcient cells and whenoxidative stress is generated in peroxisomes, indicating a direct
cross-talk between these two organelles on redox homeostasis, as
discussed later [96–98]. Thus, a systematic assessment of addi-
tional cellular sources of ROS in X-ALD (peroxisomes, xanthine
oxidase, NADPH oxidases) in relevant models for the disease, such
as primary cultures of neural cells or, ideally, in vivo in the mouse
nervous system, is warranted.
The molecular mechanisms by which the VLCFA excess triggers
oxidative stress in mitochondria in X-ALD is far from clear. We
hypothesize that excess of C26:0 could alter the permeability of
the inner mitochondrial membrane, by replacing the lateral chains
of phospholipid bilayers and physically interfering with the as-
sembly or stability of OXPHOS system [52], or by increasing
membrane microviscosity [99] and provoking its disruption [100].
This could elicit electron leakage, promoting ROS generation from
the ETC. In the same manner, mitochondrial inner membrane in-
stability could allow the proton ﬂux into the matrix, decreasing
mitochondrial inner membrane potential (ΔΨm) and possibly
triggering OXPHOS dysfunction. Indeed, we revealed a defective
respiration under uncoupled conditions both in X-ALD ﬁbroblasts
and in Abcd1- spinal cords, suggesting a speciﬁc impairment of the
activity of complex V/Hþ-ATP synthase, which correlates with the
oxidation of several subunits of complex V and III of OXPHOS [52]
(Fig. 1). A similar case has been recently reported for a mouse
model of Zellweger syndrome, the PEX5 null mouse, which accu-
mulates VLCFA as much as the X-ALD model does [101]. The au-
thors show that assembly of OXPHOS is disturbed, along with
membrane ﬂuidity, leading to increased mitochondrial ROS pro-
duction [102].
Recent advances in the study of the mitochondrial permeability
transition pore (mPTP) indicate that dimeric ATP synthase is a
bona ﬁde component of the mPTP and interacts with the gate
opener cyclophilin D (CypD) [103]. We have provided evidence of
impaired mitochondrial metabolism in X-ALD ﬁbroblasts, which
cannot survive when forced to rely on mitochondrial energy pro-
duction, i.e. on incubation in galactose [36,51,52]. Oxidative stress
induced under galactose conditions leads to mitochondrial da-
mage in the form of ΔΨm dissipation, ATP drop and necrotic cell
death, together with increased expression and oxidative mod-
iﬁcations in the CypD protein [51]. Thereby, we posit that in
X-ALD, mPTP formation is favored by the increased amounts of
oxidized CypD and Complex V/Hþ-ATP synthase. Interestingly,
inhibition of CypD genetically or pharmacologically with cyclos-
porine A prevents mitochondrial dysfunction in many age-related
neurodegenerative disease models such as AD, PD, Amyotrophic
Lateral Sclerosis (ALS) and MS, indicating that CypD is a prime
therapeutic target for these disorders [104,105]. Notably, treat-
ment with antioxidants normalizes the signs of mitochondrial
damage in ﬁbroblasts from X-ALD patients, including CypD oxi-
dative modiﬁcations, and has reversed CypD induction in other
neurodegenerative disorders in vitro and in vivo [51,52,104]. These
ﬁndings provide mechanistic insight into the beneﬁcial effects of
antioxidants in neurodegenerative and non-neurodegenerative
CypD-dependent disorders (Fig. 1).
2.3.3. Defective mitochondrial biogenesis in X-ALD: targeting the
SIRT1/PGC-1α/PPARγ pathway
Besides malfunctioning of OXPHOS, signiﬁcant mitochondrial
depletion is found in the spinal cord of Abcd1- mice and in the af-
fected white matter of X-ALD patients [35,53]. We unveil that Abcd1-
mice show a 50% reduction in mitochondrial DNA copy number,
concomitant with downregulation of the mitochondrial biogenesis
pathway driven by PGC-1α/PPARγ, with diminished expression of
the biogenesis factors NRF1 and TFAM, which negatively impact on
the amounts of mitochondrial proteins such as cytochrome c,
NDUFB8 and VDAC (Fig. 1). Moreover, an excess of VLCFA may play a
Fig. 1. Model recapitulating the noxious effects of C26:0 excess on mitochondria, redox homeostasis and proteolytic machineries in the X-ALD cell. In X-ALD, excess of C26:
leads to the production of intramitochondrial ROS from the electron transport chain probably by an unknown mechanism. The consequences are mitochondrial dysfunction
resulting in loss of ΔΨm and ATP production, mPTP opening, inhibition of mitochondrial biogenesis via the SIRT1/PGC-1α/PPARγ pathway, and ultimately axonal degen-
eration. VLCFA-dependent ROS inhibit UPS and autophagy process, with axonal degeneration as fatal outcome. The pathogenic cascade can be abrogated: i) by a combination
of antioxidants; ii) by activating SIRT1 or boosting mitochondrial biogenesis with pioglitazone or resveratrol; iii) by activating autophagy via mTOR inhibition with tem-
sirolimus. These results provide potential therapies to be translated into clinical trials for AMN patients.
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were decreased by C24:0 and C26:0, in the neuronal cell line SK-NB-
E [69]. We believe that this reduction in mitochondrial amounts
exerts an impact in the axonopathy exhibited in X-ALD for the rea-
sons above mentioned. Indeed, deletion of TFAM is characterized by
decrease of both mtDNA and OXPHOS activity, correlated to axonal
degeneration and gliosis [106].
To compensate for the defective mitochondrial biogenesis, we
sought to stimulate the PGC-1α/PPARγ axis with an agonist of PPARγ,
thus treating the X-ALD mice with the thiazolidinedione pioglitazone,
widely used as antidiabetic drug [107]. On a preclinical test, piogli-
tazone satisfactorily restored redox and bioenergetic homeostasis andhalted axonal degeneration and associated locomotor disability [35]
(Fig. 1). The data lend support to repurposing pioglitazone for clinical
trials with AMN patients and reveal novel molecular mechanisms of
action of pioglitazone in neurodegeneration. Pioglitazone has recently
been granted orphan drug designation for the treatment of adreno-
leukodystrophy (EU/3/14/1245), and holds great potential for clinical
translation.
On a parallel approach, we targeted the sirtuin 1 gene (SIRT1), a
protein deacetylase that activates PGC-1α, and thus controls mi-
tochondrial content among other functions related to bioenergetics,
redox homeostasis and inﬂammation [108,109]. We found that both
transgenic overexpression of SIRT1 and a drug treatment by the
S. Fourcade et al. / Free Radical Biology and Medicine 88 (2015) 18–29 23SIRT1 activator resveratrol, normalize mitochondrial content in
spinal cords of Abcd1-null mice, along with restoring respiration,
redox and bioenergetic homeostasis, while preserving axonal health
and lomocotor capabilities [36] (Fig. 1).
The encouraging results obtained with pioglitazone and re-
sveratrol do not however allow us to discriminate between the
beneﬁts of a purely antioxidant therapy and a second strategy
combining both improved biogenesis and amelioration of oxida-
tive damage, which are most likely directly linked in this model.
Alternative approaches to protect mitochondria may include
the histone deacetylase inhibitor SAHA, which prevents energy
failure, mitochondrial depolarization, decrease of mitochondrial
amounts, along with normalizing antioxidant defences in astro-
cytes or oligodendrocytes where ABCD1 has been silenced [110].
The mechanism presumably involves induction of ABCD2.
2.3.4. 2.3.4. Oxidative stress regulates proteostasis in X-ALD: UPS
malfunction
The ubiquitin-proteasome system (UPS) is pivotal in the rapid
clearance of damaged, misfolded or aggregated proteins in both
healthy and diseased states, and has been shown to play a role in
the degradation of oxidized proteins [111,112]. Conformational
diseases involving proteasome malfunction such as polyglutamine
diseases — Huntington’s disease (HD) and several spinocerebellar
ataxias, taupathies (e.g., AD and Pick’s disease) and synucleino-
pathies (e.g., Lewy body disease) — are associated with oxidativeFig. 2. Interplay of peroxisomes, mitochondria, UPS and autophagy in redox homeostasis
in cellular redox homeostasis. Peroxisome and mitochondria are directly responsible f
degrade altered and oxydized proteins and organelles. Imbalance of redox status impac
such as mitochondrial and peroxisomal biogenesis. Thereby alteration of one this compon
and aged-related disorders such as AD, PD, HD, MS and X-ALD.stress, and in most cases oxidative damage arises very early in the
course of the pathology [90,113]. Moreover, altered UPS activity
has been observed in brain from AD, PD and ALS patients [114].
Further, selective lack of 26S proteasome subunits in sustantia
nigra results in a PD-like phenotype, whereas mice with depletion
of 26S in spinal motor neurons exhibit an ALS-like phenotype
[114], underscoring the central role of proteasomes in neurode-
generation. In X-ALD, we have detected chronic and progressive
malfunctioning of the ubiquitin-proteasome system resulting from
the accumulation of oxidatively modiﬁed proteins, some involved
in bioenergetic metabolism. Notably, the immunoproteasome (i-
proteasome) machinery appears, in the absence of overt in-
ﬂammation, upregulated in response to redox imbalance. I-pro-
teasomes are recruited to mitochondria when ﬁbroblasts are ex-
posed to an excess of C26:0, as adaptive action to oxidative stress.
Finally, antioxidant treatment regulates proteasome expression
while normalizing its function, preventing i-proteasome induction
and its translocation to mitochondria (Figs. 1 and 2). Our ﬁndings
support a key role of i-proteasomes in quality control of mi-
tochondria during oxidative damage in X-ALD [50,53]. This is
consistent with data obtained from a mouse model with defects in
the complex I subunit Ndufs4, the Ndufs4-/- mouse, which exhibits
a decrease of UPS activity [115]. UPS function is also impaired in
ﬁbroblasts from patients with mutations in complex I and complex
IV of OXPHOS [116]. Moreover, rotenone and antimycin, inhibitors
of OXPHOS complex I and III respectively, repress proteasome. Peroxisomes, mitochondria, the UPS and autophagy machineries play a major role
or ROS generation and ROS scavenging mechanisms, whereas UPS and autophagy
ts on proteostasis (UPS and autophagy), and regulates functions of both organelles
ent leads to a strong disturbance of redox homeostasis which is associated to aging
S. Fourcade et al. / Free Radical Biology and Medicine 88 (2015) 18–2924expression and activity [117]. Altogether these data suggest that
not only UPS gets clogged with an excess of oxidized proteins
during chronic oxidative stress pathologies, but also that OXPHOS
dysfunction and/or mitochondrial ROS directly shut down UPS
activity.
2.3.5. Oxidative stress regulates proteostasis in X-ALD: Autophagy
malfunction
Along with degradation by the proteasome, autophagy con-
stitutes the major route for eliminating misfolded or modiﬁed
intracellular proteins [118], and is often malfunctioning in neuro-
degenerative diseases [119]. We therefore reasoned that induction
of autophagy in X-ALD could be a plausible strategy to compensate
for proteasome’s deﬁcient activity by increasing clearance of oxi-
dized proteins. However, using the Abcd1- mouse model, we un-
expectedly detected an impairment of autophagolysosomal for-
mation and autophagic ﬂux in spinal cords. We found lesser au-
tophagolysosomes, raised p62 and decreased LC3 II levels. The
mechanism appeared to be an aberrant overactivation of the
mammalian target of rapamycin (mTOR) pathway, mediated by
VLCFA excess (Fig. 1). We thus used a speciﬁc activator of autop-
hagy through inhibition of mTOR, the rapamycin ester temsir-
olimus [120,121]. This in anticancer drug which has been used in
rodent models of AD and PD with positive results [122,123]. In our
hands, temsirolimus successfully blocked mTOR signaling, re-
stored autophagic ﬂux and arrested axonal degeneration [29], with
little to no unwanted effects [33]. Interestingly, temsirolimus ac-
tion preserved proteasome function along the way, together with
maintaining redox and metabolic homeostasis, with conserved
ATP and NADH production [33] (Fig. 1). These ﬁndings offer ﬁrst
evidence linking impaired autophagy to X-ALD, thus providing an
additional therapeutic approach to assay in clinical trials.
In a similar manner, the autophagy process is often mal-
functioning in neurodegenerative diseases [118], as well as in se-
nescence and aging, possibly related to mitochondrial oxidative
stress [124]. Indeed, ROS produced at the mitochondrial OXPHOS
sites have been described as inhibitors of autophagy [125]. For
instance, rotenone decreases autophagic ﬂux, causing lysosomal
vacuoles to accumulate in SH-SY5Y cells [126], and antimycin also
acts as an speciﬁc autophagy blocker, lowering LC3-II levels [127].
Alternative origins of ROS, such as NADPH oxidase in mdx mice,
the model of Duchenne’s muscular dystrophy, may as well pro-
vokes mTOR activation and subsequent impaired autophagy [128].
On the other hand, an intriguing link between peroxisomes,
oxidative stress and autophagy has been recently described. Per-
oxisomal ROS has been shown to suppress mTORC1 activity, in
models of the tuberous sclerosis complex signaling node TSC1 and
TSC2 proteins [129] (Fig. 2). These proteins are located in peroxi-
somes and bind to the import factors PEX19 and PEX5. This invites
careful evaluation of the sites of ROS production in the different
neural cell types in X-ALD.
Chronic oxidative stress is a hallmark of aging and may be a
major contributing factor to the well-known decline of autophagy
in aging, and thus can be a major culprit in cellular accumulation
of waste and aggregated proteins in neurodegenerative disorders.3. Role of peroxisomes in redox status and neurodegeneration
3.1. PeroxisomE-Mitochondrial CROSS TALK ON REDOX REGULATIOn
AND beyond
We have previously discussed recent evidence indicating that
oxidative damage and mitochondrial malfunction are major cul-
prits in the pathogenesis of X-ALD, as an example of cross-talk
between these organelles (Fig. 2) [58]. The concept is not novel.Besides morphological abnormalities in mitochondria found in
patients suffering from the adult form of X-ALD, adrenomyelo-
neuropathy (AMN) [130,131], additional evidence of mitochondrial
abnormalities or dysfunction in peroxisomal disease have been
reported in Zellweger syndrome [132,133]; in patients with mu-
tations in the HSD17B4 gene, which encodes for the peroxisomal
D-bifunctional enzyme [134]; and in patients suffering from the
mistargeting of peroxisomal EHHADH (peroxisomal L-bifunctional
enzyme). The latter enzyme disrupts mitochondrial metabolism
(decreasing OXPHOS activities) by interacting with the mi-
tochondrial trifunctional proteins involved in mitochondrial fatty
acid β-oxidation, HADHA and HADHB (hydroxyacyl-CoA dehy-
drogenase–3-ketoacyl-CoA thiolase–enoyl-CoA hydratase A and B)
[135]. Similar morphological abnormalities have been reported in
spinal motorneurons from Abcd1- and Abcd2-/- mice [41], in Abcd1-
adrenocortical cells [136], in multiple Pex5-/- tissues [102,137,138],
in the liver of Pex2-/- [139], in the cerebellum of Pex13-/- mice [140],
and in the Pex5 and Pex7-deﬁcient strains of Podospora Anserina,
suggesting a direct impact on mitochondria when peroxisomes are
defective.
Beyond sharing metabolic functions in the β-oxidation of fatty
acids, glyoxylate cycle and thermogenesis, these organelles exert
common functions in redox homeostasis [141]. Catalase is the best
known enzyme in peroxisomes, functioning as detoxiﬁer of hy-
drogen peroxide [142]. Using speciﬁc probes able to discriminate
between ROS produced in peroxisomes, cytoplasm and mi-
tochondria, and also using a photosensitizer KillerRed protein
generating ROS in these compartments, elegant experimental
work from the group of Marc Fransen has shed light into the in-
tricacies of redox regulation between these organelles [143].
Indeed, loss of peroxisomal catalase, and subsequent peroxi-
some-derived oxidative stress, induces redox imbalance in mi-
tochondria, whereas no effect is observed in the cytoplasm. How-
ever, this relationship is non-reciprocal, as redox status is main-
tained in peroxisomes when ROS are generated inside mitochondria
[97]. Further, an excess of peroxisomal ROS triggers mitochondrial
fragmentation with subsequent cell death which is prevented by
lipoic acid and L-histidine, a singlet oxygen quencher [98]. Similar
protective effects were observed upon overexpression of antioxidant
enzymes: catalase in the mitochondria, or GSTK1 (Glutathione
S-transferase kappa 1) and SOD1 (Superoxide dismutase 1) in per-
oxisomes [98]. Finally, cells lacking functional peroxisomes (loss of
Pex5, Pex19 or glycerone phosphate acyl transferase (GNPAT), which
participates to plasmalogen synthesis), showed marked sensitization
to cell death induced by oxidative stress originating from peroxi-
somes, mitochondria or the cytoplasm [98].
Besides mitochondrial fragmentation and subsequent cell death,
there is unambiguous demonstration of direct detrimental effects of
ROS excess on essential peroxisomal functions, such as pexophagy
(the autophagic degradation of peroxisomes) and peroxisome bio-
genesis [144]. In particular, peroxisome biogenesis, peroxisomal
content and division processes are controlled by oxidative stress via
the redox-sensitive peroxins PEX5 [145], PEX11β [146] and PMP14
[147]. It is worth noting that the fundamental elements of mi-
tochondrial ﬁssion/fusion machinery, the FIS1 and DRP1 proteins,
are also regulating peroxisomal dynamics [148–150]. Remarkably,
aberrant S-nitrosylation of DRP1 induces its GTPase activity, which is
associated with mitochondria ﬁssion in AD and HD [151]. Non-sur-
prisingly, the peroxisome proliferator-activated receptor PPARγ and
PPARα agonists orchestrate both peroxisomal and mitochondrial
ﬁssion-fusion dynamics [152–154].
3.2. The role of peroxisomes in neurodegeneration
Excess of VLCFA exerts toxicity on neural cell types, as reported
by several laboratories (Lizard G, Reiser G and Singh I labs).
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oligodendrocytes and astrocytes, with doses of VLCFA ranging
from 20 to 40 mM depending on the cell types [66–68,95]. How-
ever, no cell death was shown by these teams when ABCD1 was
silenced in murine oligodendrocyte cell line [67] or primary as-
trocyte culture generated from Abcd1-null mice [95]. In contrast,
Singh’s lab described cell death after ABCD1 loss, in rat B12 oli-
godendrocytic cells, but not in human U87 astrocytes, suggesting
that oligodendrocytes are more sensitive to ABCD1 knockdown
than astrocytes [155]. This higher sensitivity of oligodendrocytes
to VLCFA but not the other neural cell types is consistent to the
axonal loss and demyelination found out when functional per-
oxisomes are absent in oligodendrocytes [156] but not in astro-
cytes nor neurons [157]. However, neither oligodendrocyte loss
nor demyelination has been observed in X-ALD mouse models
[18,40] indicating that ABCD1 deletion, alone, is not sufﬁcient to
kill oligodendrocytes in vivo in the mouse. Therefore, we posit that
unknown factors which protect oligodendrocytes in vivo ought to
exist, which may be differentially activated in oligodendrocytes
lacking of ABCD1 and ABCD2, compared with loss of functional
peroxisomes in the same cells.
There is growing evidence, gained mostly from conditional
transgenesis experiments in the mouse, of the pivotal role played
by peroxisomes in nervous system development and maintenance,
in particular in myelin sheaths. Selective loss of functional per-
oxisomes in oligodendrocytes leads to demyelination and axonal
loss in Cnp-Pex5mice, after having exhibited a normal myelination
process during the ﬁrst months of life [156]. Absence of peroxi-
somes in astrocytes provokes defects in the myelin with increase
of VLCFA content but no axonal loss nor demyelination. This im-
plies that an excess of VLCFA levels in the myelin is not sufﬁcient
to exert a major direct impact on neurological functioning [157].
Similarly, mice with speciﬁc deletion of Pex5 in neurons (Nex-
Pex5) exhibit no metabolic disturbance neither axonal damage
[157]. Finally, Nestin-Pex5 mice, which harbor a deletion of Pex5 in
the central and peripheral nervous system (of expression in oli-
godendrocytes, neurons, astrocytes and microglial cells), show an
earlier onset phenotype than Cnp-Pex5 mice, which exhibit de-
myelination and axonal abnormalities associated with locomotor
and cognitive deﬁcits [158]. This suggests that peroxisomes of
neurons, astrocytes and microglia contribute to some degree to
myelin maintenance when peroxisomal functions are abrogated in
oligodendrocytes devoid of the organelles.
Aging is characterized by a progressive loss of physiological
integrity, leading to impaired cellular function, increased vulner-
ability to insults and decreased regenerative capacities. Redox
status, mitochondrial ﬁtness and proteolysis capacities are affected
during and may contribute to aging [159] (Fig. 2). As noted else-
where, peroxisomes are involved in these different processes,
suggesting an as-yet-poorly explored role of the organelle in aging
(Fig. 2). A few reports support this notion; it has been observed
that peroxisome morphology is altered with age in rodent hepa-
tocytes [160] and peroxisomal ROS are elevated which impacts
mitochondria in a vicious cycle [97]. As a consequence of excess of
ROS with aging, peroxisome biogenesis is decreased, as some
peroxins (PEX5, PEX14, PEX11β) involved in this process are redox-
sensitive [43], thus leading to a general decrease of peroxisomal
functions during aging, which may contribute to the aging process
itself [160].
This notion is underlined by the observed peroxisomal altera-
tions in Alzheimer’s (AD) and Multiple Sclerosis (MS) patients, as
well as in Parkinson’s disease (PD), which may contribute to these
pathologies. For instance, in AD patients with Braak V-VI stage,
VLCFA are elevated and plasmalogens lowered (Fig. 2). Both are
good indicators of peroxisomal malfunction, and are directly cor-
related to the amount of neuroﬁbrillary tangles but not to amyloidplaques [161]. Peroxisomes but not mitochondria are absent in
neuronal processes with phosphorylated TAU [161], which may
indicate a selective toxicity of phosphoTAU to peroxisomes.
Moreover, a direct link has been demonstrated between DHA —
the major polyunsaturated fatty acid in the brain, which is syn-
thesized by peroxisomes — and AD. Indeed, dietary supple-
mentation with DHA in the 3xTg AD mouse model reduced both
types of β-amyloid ﬁbrils, the soluble form and the Aβ-plaques
[162,163]. Moreover, an alteration in peroxisomal protein contents
(induction of ABCD3, Acyl-coA oxidase and Pex5, concomitant
with a reduction of thiolase and catalase in the hippocampus) was
readily observed at early stages of pathology in the Tg2576 AD
mouse model [164]. In MS patients, VLCFA are increased in grey
matter, consistent with a decrease of peroxisomes in grey matter
neurons [165]. Peroxisomes have also been linked to PD [132].
Firsthly, aggregation of α-synuclein in the brain of Pex2-/-, Pex5-/-
and Pex7-/- mice was evidenced, and Lewy-like inclusions were
formed when α-synuclein thereby was overexpressed in Pex5-/-
ﬁbroblasts [166]. Further, reduced catalase activity was reported in
the brains of A53T α-synuclein mice, which was then correlated to
lower expression of other peroxisomal genes such as ABCD3,
AcylCoA oxidase and PEX14, and to raised carbonyls levels. How-
ever, no accumulation of phytanic acid, pristanic acid or VLCFA was
observed in these mice, indicating that neither peroxisomal α- nor
β-oxidation were altered in the PD mouse model at this age [167].
Altogether, these data suggest that peroxisomes may contribute
directly to neurodegeneration, or indirectly via cross-talk with
mitochondria in redox homeostasis [94,95] (Fig. 2).4. Concluding remarks
Compelling evidence indicates that X-ALD recapitulates the pa-
thological hallmarks of the main neurodegenerative disorders, with
intertwined peroxisomal, mitochondrial, proteasomal and autop-
hagy dysfunction. Neutralization of ROS prevents these alterations
along with axonal degeneration, which indicates that oxidative
stress is a major culprit in this disease. Thus, therapeutic strategies
that hold therapeutic potential may include: i) Antioxidants targeted
to mitochondria and/or protectors of mitochondrial membranes; ii)
Mitochondrial biogenesis boosters for generation of new, intact
mitochondria; iii) Activators of intrinsic antioxidant pathways like
autophagy and the proteasome, which will remove damaged or
dysfunctional proteins and organelles, and can be considered as
endogenous antioxidant systems; and iv) A combination of the
above (Fig. 1). Thus, the identiﬁcation and validation of biomarkers
to monitor optimal dosing and biological efﬁcacy of the antioxidant
treatments is of prime interest. We have formerly used MALDI-TOF
to identify a set of quantitative oxidative lesion markers to proteins
(GSA, AASA, CEL, CML and MDAL) in murine nervous tissue of the
Abcd1- mouse [49], in peripheral mononuclear cells of AMN patients
[46], and are currently in the process of validating them in a larger
setting, a phase II clinical trial with a combination of antioxidants for
AMN patients (NCT1495260).
X-ALD, a rare monogenic peroxisomal disorder, may constitute
a suitable paradigm to dissect molecular mechanisms and altered
pathways in neurodegeneration, and thus a model to uncover new
disease-modifying treatments that may also help in other, multi-
factorial or inherited neurodegenerative diseases in which axonal
degeneration is at the bulk of clinical symptoms.
We posit that neurodegenerative disorders may be considered as
secondary peroxisomal and mitochondrial disorders to some extext,
in which redox homeostasis and proteostasis plays a major role in the
neurodegenerative cascade and thus, constitute prime therapeutic
targets. The scenario is however complex, and precludes straight-
forward extrapolation of conclusions from one model to another from
S. Fourcade et al. / Free Radical Biology and Medicine 88 (2015) 18–2926arising, while inviting to a cautious examination of the speciﬁc pa-
thomechanisms operating in every particular disease model prior to
designing the most suitable therapies (Fig. 2).Funding
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